Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced
In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit